🚀 VC round data is live in beta, check it out!
Diaceutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Diaceutics and similar public comparables like Korro Bio, Alpha Teknova, Quantum-Si, OmniAb and more.
Diaceutics Overview
About Diaceutics
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides the pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine, enabled by DXRX The Diagnostic Network. DXRX is the diagnostic commercialization platform designed specifically for precision medicine, integrating multiple pipelines of real-world, real-time diagnostic testing data from a network of labs. These solutions are helping the pharma companies commercialize their precision medicines, enhance their return on investment and ultimately improve patients' lives. Geographically, it operates in UK, North America, Europe, and Asia and Rest of World.
Founded
2005
HQ
Employees
199
Website
Sectors
Financials (LTM)
EV
$176M
Diaceutics Financials
Diaceutics reported last 12-month revenue of $56M and EBITDA of $11M.
In the same LTM period, Diaceutics generated $48M in gross profit, $11M in EBITDA, and had net loss of ($287K).
Revenue (LTM)
Diaceutics P&L
In the most recent fiscal year, Diaceutics reported revenue of $43M and EBITDA of $4M.
Diaceutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $56M | XXX | $43M | XXX | XXX | XXX |
| Gross Profit | $48M | XXX | $38M | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | $11M | XXX | $4M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 9% | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | (8%) | XXX | XXX | XXX |
| Net Profit | ($287K) | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | (1%) | XXX | (5%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Diaceutics Stock Performance
Diaceutics has current market cap of $189M, and enterprise value of $176M.
Market Cap Evolution
Diaceutics' stock price is $2.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $176M | $189M | 0.0% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDiaceutics Valuation Multiples
Diaceutics trades at 3.2x EV/Revenue multiple, and 15.9x EV/EBITDA.
EV / Revenue (LTM)
Diaceutics Financial Valuation Multiples
As of April 20, 2026, Diaceutics has market cap of $189M and EV of $176M.
Equity research analysts estimate Diaceutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Diaceutics has a P/E ratio of (657.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $189M | XXX | $189M | XXX | XXX | XXX |
| EV (current) | $176M | XXX | $176M | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | 15.9x | XXX | 47.0x | XXX | XXX | XXX |
| EV/EBIT | 206.4x | XXX | (53.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 3.7x | XXX | 4.6x | XXX | XXX | XXX |
| P/E | (657.5x) | XXX | (82.0x) | XXX | XXX | XXX |
| EV/FCF | (180.5x) | XXX | (32.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Diaceutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Diaceutics Margins & Growth Rates
Diaceutics' revenue in the last 12 month grew by 24%.
Diaceutics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Diaceutics' rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Diaceutics' rule of X is 87% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Diaceutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 40% | XXX | 163% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 48% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 87% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 80% | XXX | 96% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 96% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Diaceutics Public Comps
See public comps and valuation multiples for other Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Diaceutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Korro Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Alpha Teknova | XXX | XXX | XXX | XXX | XXX | XXX |
| Quantum-Si | XXX | XXX | XXX | XXX | XXX | XXX |
| OmniAb | XXX | XXX | XXX | XXX | XXX | XXX |
| Bioventix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Diaceutics M&A Activity
Diaceutics acquired XXX companies to date.
Last acquisition by Diaceutics was on XXXXXXXX, XXXXX. Diaceutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Diaceutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDiaceutics Investment Activity
Diaceutics invested in XXX companies to date.
Diaceutics made its latest investment on XXXXXXXX, XXXXX. Diaceutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Diaceutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Diaceutics
| When was Diaceutics founded? | Diaceutics was founded in 2005. |
| Where is Diaceutics headquartered? | Diaceutics is headquartered in United Kingdom. |
| How many employees does Diaceutics have? | As of today, Diaceutics has over 199 employees. |
| Who is the CEO of Diaceutics? | Diaceutics' CEO is Ryan Keeling. |
| Is Diaceutics publicly listed? | Yes, Diaceutics is a public company listed on London Stock Exchange. |
| What is the stock symbol of Diaceutics? | Diaceutics trades under DXRX ticker. |
| When did Diaceutics go public? | Diaceutics went public in 2019. |
| Who are competitors of Diaceutics? | Diaceutics main competitors are Korro Bio, Alpha Teknova, Quantum-Si, OmniAb. |
| What is the current market cap of Diaceutics? | Diaceutics' current market cap is $189M. |
| What is the current revenue of Diaceutics? | Diaceutics' last 12 months revenue is $56M. |
| What is the current revenue growth of Diaceutics? | Diaceutics revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of Diaceutics? | Current revenue multiple of Diaceutics is 3.2x. |
| Is Diaceutics profitable? | Yes, Diaceutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Diaceutics? | Diaceutics' last 12 months EBITDA is $11M. |
| What is Diaceutics' EBITDA margin? | Diaceutics' last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Diaceutics? | Current EBITDA multiple of Diaceutics is 15.9x. |
| What is the current FCF of Diaceutics? | Diaceutics' last 12 months FCF is ($977K). |
| What is Diaceutics' FCF margin? | Diaceutics' last 12 months FCF margin is (2%). |
| What is the current EV/FCF multiple of Diaceutics? | Current FCF multiple of Diaceutics is (180.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.